Vivoryon Therapeutics N.V. (0R3M) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning or good afternoon, everyone, and thank you for joining us today for Vivoryon's first half twenty twenty six results call. Earlier today, we issued a press release reporting our first half twenty twenty six financial results and business update, which can be found on Vivoryon's website at www.vivariant.com. On the call with me today are Frank Weber, our Chief Executive Officer Markus Erstfeld, our Chief Financial Officer as well as Mikhail Schafer, our Chief Business Officer. Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward looking statements concerning future transactions, the development of Vivoryon's core platform, the progress of its research and development programs, and the initiation of additional programs, as well as results of operations, cash needs, financial conditions, liquidity prospects, and strategies. Should actual results differ from the company's assumptions, ensuing actions may differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. As you can see on the agenda for today's call, I will begin with an overview of our progress throughout the first half of twenty twenty six as we continue to advance our strategic priorities and strengthen the body of evidence for vargumentumab in kidney disease. I will then hand the call over to Michel, who will share some new preclinical data which provides further insights into the mechanism of action underlying the compelling data we have seen with raglutidem in clinical studies. Frank will then share details on the ongoing momentum behind our strategic partnering discussion. He will be followed by Markus, who will review the f...